HADAŠOVÁ, Eva, Alexandra ŽOURKOVÁ, Josef TOMANDL and Barbora RAVČUKOVÁ. Dynamics of CYP2D6 activity and clinical response to paroxetine, alprazolam and their combination in patients with depressive disorder. Chemické listy. Praha: Česká spol. chemická, 2003, 97 (S), červen, p. S180, 1 pp. ISSN 0009-2770.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Dynamics of CYP2D6 activity and clinical response to paroxetine, alprazolam and their combination in patients with depressive disorder
Authors HADAŠOVÁ, Eva (203 Czech Republic, guarantor), Alexandra ŽOURKOVÁ (203 Czech Republic), Josef TOMANDL (203 Czech Republic) and Barbora RAVČUKOVÁ (203 Czech Republic).
Edition Chemické listy, Praha, Česká spol. chemická, 2003, 0009-2770.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.345
RIV identification code RIV/00216224:14110/03:00008962
Organization unit Faculty of Medicine
Keywords in English Genetic polymorphism; CYP2D6; paroxetine; alprazolam; psychiatric patients
Tags alprazolam, CYP2D6, genetic polymorphism, paroxetine, psychiatric patients
Changed by Changed by: prof. MUDr. Eva McCaskey Hadašová, CSc., učo 709. Changed: 14/10/2003 12:07.
Abstract
Dynamics of the paroxetine-induced inhibition of CYP2D6 was followed during the paroxetine therapy in patients using phenotyping and genotyping methods. Another aim of the study was to evaluate the level of the enzyme restoration after discontinuation of the paroxetine treatment. The study has shown that even a profound inhibition of CYP2D6 activity in patients without mutation in the CYP2D6 locus had only minor clinical relevance for treatment effectivity and occurence of adverse effects.
PrintDisplayed: 29/9/2024 03:10